dulaglutide vs Tifeglipron
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: April 2027 · NCT07537088 (registry estimate)
Reported efficacy
Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) (met)
Result source: NCT03495102
Tifeglipron
Developed by Roche
NCT05814107 · Phase 1 · completed
This is a randomized, double-blind, placebo-controlled study, but it is an early-phase dose-finding and safety study whose primary measured outcome is adverse events rather than a disease or weight-related outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment-Emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2028 · NCT07112872 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dulaglutide | Tifeglipron |
|---|---|---|
| HbA1c, change | -2.0% vs -1.1%−0.9 vs placeboNCT0459162625 other results
| —Not reported |
| Body weight, change (kg) | -0.8 vs 0.4−1.2 vs placeboNCT0459162618 other results
| —Not reported |
| HbA1c below 7% | 75.9% vs 33.8%+42.1 vs placeboNCT045916268 other results
| —Not reported |
| Fasting plasma glucose, change | -2.2 vs -2.4vs Insulin GlargineNCT016485823 other results
| —Not reported |
| 3-point MACE (% with event) | 12% vs 13.4%−1.4 vs placeboNCT013949521 other result
| —Not reported |
HbA1c, change
- dulaglutide
- -2.0% vs -1.1%−0.9 vs placeboNCT04591626
25 other results
- -1.3% vs -0.5% NCT02597049
- -1.3% vs -0.5% NCT02597049
- -1.2% vs -0.5% NCT02597049
- -1.2% vs -0.5% NCT02597049
- -1.4% vs -0.7% NCT02152371
- -1.4% vs -0.1% NCT01769378
- -1.2% vs -1.1% NCT01621178
- -1.7% vs -1.2% NCT01648582
- -1.5% vs -0.9% NCT01644500
- -1.4% vs -1.4% NCT01624259
- -1.1% vs -1.1% NCT01621178
- -1.3% vs -1.2% NCT01648582
- -1.2% vs -0.9% NCT01644500
- -1.4% vs -0.9% NCT01584232
- -1% vs 0.5% NCT02963766
- -0.5% vs 0.5% NCT02963766
- -0.9% vs -1.7% NCT04255433
- -1.1% vs -1% NCT01621178
- -1.5% vs -0.9% NCT01648582
- -1.1% vs -1% NCT01621178
- -1.0% vs -0.9% NCT01648582
- -1.4% vs -0.4% NCT02973100
- -1.3% vs -0.4% NCT02973100
- -1.2% vs -0.4% NCT02973100
- -1.4% vs 0.1% NCT02750410
- Tifeglipron
- —Not reported
Body weight, change (kg)
- dulaglutide
- -0.8 vs 0.4−1.2 vs placeboNCT04591626
18 other results
- -1.9 vs 0.5 NCT02152371
- -0.9 vs -0.2 NCT01769378
- -2.7 vs 1.6 NCT01621178
- -1.1 vs 1.4 NCT01648582
- -2.8 vs 1.1 NCT01621178
- -1.5 vs 1.0 NCT01648582
- -1.5 vs 0.9 NCT01644500
- -2.9 vs -3.6 NCT01624259
- -1.7 vs 1.6 NCT01621178
- -0.8 vs 1.4 NCT01648582
- -2.0 vs 1.1 NCT01621178
- -0.9 vs 1.0 NCT01648582
- -0.8 vs 0.9 NCT01644500
- -0.5 vs 0.9 NCT01584232
- -4.1 vs -1.6 NCT02973100
- -3.9 vs -1.6 NCT02973100
- -2.8 vs -1.6 NCT02973100
- -0.2 vs -0.3 NCT02750410
- Tifeglipron
- —Not reported
HbA1c below 7%
- dulaglutide
- 75.9% vs 33.8%+42.1 vs placeboNCT04591626
8 other results
- 32.9% vs 29.1% NCT01621178
- 37.5% vs 34.6% NCT01621178
- 33.5% vs 29.1% NCT01621178
- 31.7% vs 34.6% NCT01621178
- 68.2% vs 20% NCT02973100
- 71.2% vs 20% NCT02973100
- 71.2% vs 20% NCT02973100
- 0% vs 47.4% NCT02750410
- Tifeglipron
- —Not reported
Fasting plasma glucose, change
- dulaglutide
- -2.2 vs -2.4vs Insulin GlargineNCT01648582
3 other results
- -2.4 vs -2.6 NCT01648582
- -1.5 vs -2.4 NCT01648582
- -1.7 vs -2.6 NCT01648582
- Tifeglipron
- —Not reported
3-point MACE (% with event)
- dulaglutide
- 12% vs 13.4%−1.4 vs placeboNCT01394952
1 other result
- 13.1% vs 12.2% NCT04255433
- Tifeglipron
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Tifeglipron: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. dulaglutide: 4 of 4 rows · Tifeglipron: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | dulaglutide |
|---|---|
| Dropout rate | 0.3%a NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results4.4% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 8.8%4.5 mg NCT03495102 · Phase 3 10.9%3 mg NCT03495102 · Phase 3 9.2%1.5 mg NCT03495102 · Phase 3 —1.5 mg NCT01621178 · Phase 3 —0.75 mg NCT01621178 · Phase 3 3.8%1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 3.9%0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 2.5%Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence — NCT03315780 · Phase 4 · registry result, not featured evidence 2.2%1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 3.1%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 4.9%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 3.5%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 8% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 12.4%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 14.8%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 10.4% NCT01769378 · Phase 3 · registry result, not featured evidence 9%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 9.7%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence —1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence 10%LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 9.2%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 5.1%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence — NCT01458210 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 16.7% NCT01436201 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results1.7% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.6%4.5 mg NCT03495102 · Phase 3 1.1%3 mg NCT03495102 · Phase 3 0.8%1.5 mg NCT03495102 · Phase 3 —1.5 mg NCT01621178 · Phase 3 —0.75 mg NCT01621178 · Phase 3 1.9%1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 0%0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 1.7%Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence — NCT03315780 · Phase 4 · registry result, not featured evidence —1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 0%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 1.4%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 0%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 4% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 2.3%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 4.3%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 4.2% NCT01769378 · Phase 3 · registry result, not featured evidence 2.5%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 0.4%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence —1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence 6%LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 2.6%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 1.3%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence — NCT01458210 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 8.3% NCT01436201 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 40.3%a NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results5% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.2%4.5 mg NCT03495102 · Phase 3 7.3%3 mg NCT03495102 · Phase 3 8.7%1.5 mg NCT03495102 · Phase 3 21.4%1.5 mg NCT01621178 · Phase 3 25.3%0.75 mg NCT01621178 · Phase 3 —1.5 mg NCT02963766 · Phase 3 1.9%1.5 mg NCT02963766 · Phase 3 4%1.5 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 2%0.75 mg NCT02963766 · Phase 3 2%0.75 mg NCT02963766 · Phase 3 0%1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence 0%0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence 2.5%0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 5%0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence 0% NCT03315780 · Phase 4 · registry result, not featured evidence 31.9%1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence 3.8%1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 3.6%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence 5.6%1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 3.5%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 2.1%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 6% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 9.3%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 5.8%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 3.8% NCT01769378 · Phase 3 · registry result, not featured evidence 2.5%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 1.6%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence 1.7%1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence —LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 3.9%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 8.9%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence 3.7%1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 9.1%0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0% NCT01458210 · Phase 1 · registry result, not featured evidence · combination 0%Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination 0%Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 0% NCT01436201 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a nausea 14.9% (placebo 5.4%) diarrhoea 13.5% (placebo 8.8%) nasopharyngitis 11.4% (placebo 10.8%) NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 41 more resultsnasopharyngitis 27.1% diarrhoea 12.2% nausea 9.4% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5 mg diarrhoea 21.2% (placebo 13.7%) headache 15.4% (placebo 9.8%) nausea 15.4% (placebo 7.8%) NCT02963766 · Phase 3 1.5 mg diarrhoea 12% (placebo 13.7%) nausea 12% (placebo 7.8%) abdominal pain upper 10% (placebo 7.8%) NCT02963766 · Phase 3 0.75 mg vomiting 17.6% (placebo 3.9%) diarrhoea 15.7% (placebo 13.7%) headache 13.7% (placebo 9.8%) NCT02963766 · Phase 3 0.75 mg headache 10.2% (placebo 9.8%) vomiting 8.2% (placebo 3.9%) abdominal pain 6.1% (placebo 5.9%) NCT02963766 · Phase 3 1.5 mg gastritis 14.3% dyslipidaemia 9.5% nausea 9.5% NCT05659537 · Phase 4 · registry result, not featured evidence 0.75 mg anaemia 21.4% gastritis 14.3% dyslipidaemia 7.1% NCT05659537 · Phase 4 · registry result, not featured evidence 0.75 mg nasopharyngitis 15.8% (placebo 30.8%) abdominal discomfort 8.3% (placebo 12.8%) constipation 6.7% (placebo 12.8%) NCT02750410 · Phase 4 · registry result, not featured evidence 0.75 mg nasopharyngitis 28.3% (placebo 30.8%) constipation 10.8% (placebo 12.8%) abdominal discomfort 9.2% (placebo 12.8%) NCT02750410 · Phase 4 · registry result, not featured evidence influenza 16.7% (placebo 0%) decreased appetite 8.3% (placebo 0%) diarrhoea 8.3% (placebo 8.3%) NCT03315780 · Phase 4 · registry result, not featured evidence 1.5 mg nausea 22.3% diarrhoea 18.9% covid-19 15.1% NCT04255433 · Phase 3 · registry result, not featured evidence 1.5 mg constipation 12.5% diarrhoea 10.2% pyrexia 10% NCT04809220 · Phase 3 · registry result, not featured evidence 0.75 mg constipation 8.7% nasopharyngitis 8.7% covid-19 8.2% NCT04809220 · Phase 3 · registry result, not featured evidence 1.5 mg decreased appetite 22.2% (placebo 4.1%) diabetic nephropathy 13.9% (placebo 15%) diarrhoea 13.2% (placebo 8.2%) NCT04591626 · Phase 3 · registry result, not featured evidence · add on 1.5 mg nausea 14.8% (placebo 3.6%) back pain 9.2% (placebo 7.1%) viral upper respiratory tract infection 6.3% (placebo 7.9%) NCT02597049 · Phase 3 · registry result, not featured evidence 0.75 mg diarrhoea 9.9% (placebo 2.9%) back pain 8.5% (placebo 7.1%) viral upper respiratory tract infection 5.7% (placebo 7.9%) NCT02597049 · Phase 3 · registry result, not featured evidence nausea 12% (placebo 1.3%) diarrhoea 11.3% (placebo 4%) upper respiratory tract infection 7.3% (placebo 6.7%) NCT02152371 · Phase 3 · registry result, not featured evidence · combination 1.5 mg hyperlipidaemia 17.8% diarrhoea 16.7% lipase increased 10.5% NCT01648582 · Phase 3 · registry result, not featured evidence 0.75 mg hyperlipidaemia 19.5% diarrhoea 10.9% hypertension 10.9% NCT01648582 · Phase 3 · registry result, not featured evidence nausea 10.5% (placebo 0%) diarrhoea 8.4% (placebo 0%) eructation 5.9% (placebo 0%) NCT01769378 · Phase 3 · registry result, not featured evidence 1.5 mg diarrhoea 17.2% hyperlipidaemia 11.1% nausea 10.2% NCT01644500 · Phase 3 · registry result, not featured evidence 0.75 mg hyperlipidaemia 12.1% diarrhoea 7.3% lipase increased 5.6% NCT01644500 · Phase 3 · registry result, not featured evidence 1.5 mg weekly nausea 20.4% diarrhoea 12% dyspepsia 8% NCT01624259 · Phase 3 · registry result, not featured evidence 4.5 mg nausea 30.3% (placebo 4.9%) diarrhoea 21.1% (placebo 11.1%) vomiting 13.2% (placebo 4.9%) NCT02973100 · Phase 2 · registry result, not featured evidence 3.0 mg nausea 25.3% (placebo 4.9%) diarrhoea 22.8% (placebo 11.1%) decreased appetite 16.5% (placebo 1.2%) NCT02973100 · Phase 2 · registry result, not featured evidence 1.5 mg nausea 22.2% (placebo 4.9%) diarrhoea 11.1% (placebo 11.1%) vomiting 11.1% (placebo 4.9%) NCT02973100 · Phase 2 · registry result, not featured evidence 1.5 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) blood pressure decreased 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 1.5 mg abdominal discomfort 10% (placebo 6.3%) decreased appetite 10% (placebo 0%) nausea 10% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.75 mg abdominal discomfort 9.1% (placebo 6.3%) nausea 9.1% (placebo 0%) vomiting 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.75 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) abdominal distension 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.5 mg abdominal discomfort 0% (placebo 6.3%) abdominal distension 0% (placebo 0%) abdominal pain 0% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.5 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) abdominal pain 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence headache 41.2% nausea 41.2% vomiting 35.3% NCT01458210 · Phase 1 · registry result, not featured evidence · combination diarrhoea 8% haemorrhoids 4% injection site pain 4% NCT01432938 · Phase 1 · registry result, not featured evidence · combination vomiting 11.5% decreased appetite 7.7% headache 7.7% NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy gastrooesophageal reflux disease 33.3% atrioventricular block first degree 28.6% headache 28.6% NCT01436201 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
dulaglutide
show 1 more result
show 25 more results
show 18 more results
show 6 more results
show 4 more results
show 2 more results
+ 65 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · Tifeglipron's landscape